A Pulmonary Expert Weighs in on the Johnson & Johnson COVID-19 Vaccine’s Pause

The mission of Health Matters is to promote health equity by elevating the conversation around healthy habits, preventative health, and relevant public health issues. By approaching these topics with an equitable lens, we can all do our part to empower individuals to make more informed decisions about their health and care.

 

On this episode, hosts Dr. Jose Medina-Inojosa and Alisa Johnsrud talked with Jonathan Baktari, MD, about the Johnson and Johnson vaccine pause due to potentially fatal blood clots after one American died and one is in critical condition. Baktari is a pulmonary and critical care expert, vaccine expert, CEO of two medical companies —e7Health.com and US Drug Test Centers.

“It’s interesting. The mRNA vaccine has been around for ten years” -Jonathan Baktari, MD

The trio talked about the Johnson and Johnson vaccine and the importance of the other vaccines. Baktari said the vaccine would be part of the solution to get to herd immunity, so even though it’s currently delayed, it will be an essential piece of the puzzle. The Moderna and Pfizer vaccine use mRNA to introduce the virus, while the J&J vaccine uses the adenovirus.

“It’s interesting. The mRNA vaccine has been around for ten years,” Baktari said. He elaborated that nobody had the guts to use mRNA because folks would have been hesitant to inject genetic material. The pandemic, however, forced us to use the technology.

Vaccines have always been a sensitive subject, as some don’t want to use vaccines. For Baktari, he doesn’t understand the hesitancy. He noted that people are still so willing to use antibiotics and other drugs, but they don’t like it when it comes to vaccines. One of the reasons he thinks is because the government advises it.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

Leadership
How the Future of Work Is Being Reshaped by AI, Human Creativity, and Customer-Centered Leadership
May 21, 2026

As artificial intelligence rapidly reshapes industries, many professionals are asking the same urgent question: what happens when AI starts replacing not just repetitive tasks, but the foundational entry-level roles that once launched careers? According to Goldman Sachs Research, AI could expose the equivalent of 300 million jobs globally to automation, while potentially automating tasks…

Read More
finance
Dr. Silver Kung’s Path From $10 Million in Debt to a Multibillion-Dollar Finance Career
May 21, 2026

Global finance is being tested by forces that no balance sheet can fully predict: unstable supply chains, geopolitical shocks, tighter credit conditions and the accelerating rise of AI. In trade finance especially, success depends on more than capital; it requires judgment, discipline and the ability to see risk before it becomes disruption. As automation…

Read More
specialty pharmacy
At the Center of Care: How Specialty Pharmacy Aligns Patients, Providers, and Payers
May 21, 2026

As healthcare costs continue to rise, more patients are finding themselves navigating not just illness, but the growing complexity of paying for treatment. Specialty pharmacy sits right at the center of that challenge—often out of sight, but increasingly essential to how modern care actually works. These high-cost, high-touch therapies now make up more than…

Read More
Language development
Just Thinking… About How Multilingualism and Language Development Belong at the Center of Student Learning
May 20, 2026

For millions of students in America, learning English is only one part of a much larger academic story. A 2024 GAO report found that English learners in U.S. public schools grew from 4.5 million to 5 million students between fall 2010 and fall 2020, and that they speak more than 400 languages. That diversity…

Read More